Evidence map›Paper›PMID 38237594›Full record

ArticleAmerican journal of human genetics2024

Regulatory features aid interpretation of 3'UTR variants.

Lindsay Romo, Scott D Findlay, Christopher B Burge

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. TACR3 variant confers resilience to aging and Alzheimer's disease.medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Lindsay RomoHarvard Medical Genetics Training Program, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: lindsay.romo@childrens.harvard.edu.
Scott D FindlayDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Christopher B BurgeDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. Electronic address: cburge@mit.edu.
Massachusetts Institute of Technology · USBoston Children's Hospital · US

Funding

Regulation and Function of Alternative mRNA Isoform Expression in MammalsR01HG002439 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2002 to 2024
$9.7M
Identification and Function of Sequence-specific Splicing RegulatorsR01GM085319 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2008 to 2025
$5.2M
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer TherapiesR01CA226898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B, HEMANN, MICHAEL · 2019 to 2023
$2.7M
NCI NIH HHS R01 CA226898NHGRI NIH HHS R01 HG002439NIGMS NIH HHS R01 GM085319
6 · The paper itself

Abstract

Our ability to determine the clinical impact of variants in 3' untranslated regions (UTRs) of genes remains poor. We provide a thorough analysis of 3' UTR variants from several datasets. Variants in putative regulatory elements, including RNA-binding protein motifs, eCLIP peaks, and microRNA sites, are up to 16 times more likely than variants not in these elements to have gene expression and phenotype associations. Variants in regulatory motifs result in allele-specific protein binding in cell lines and allele-specific gene expression differences in population studies. In addition, variants in shared regions of alternatively polyadenylated isoforms and those proximal to polyA sites are more likely to affect gene expression and phenotype. Finally, pathogenic 3' UTR variants in ClinVar are up to 20 times more likely than benign variants to fall in a regulatory site. We incorporated these findings into RegVar, a software tool that interprets regulatory elements and annotations for any 3' UTR variant and predicts whether the variant is likely to affect gene expression or phenotype. This tool will help prioritize variants for experimental studies and identify pathogenic variants in individuals.

Indexed as

MicroRNAs3' Untranslated RegionsCell LineHumansProtein BindingRegulatory Sequences, Nucleic Acid3' Untranslated RegionsMicroRNAs3ʹ UTRgenetic variantsmiRNApolyadenylationregulatory motifsRNA-binding proteinsvariant interpretation

Identifiers

PMID38237594
PMCPMC10870128
OpenAlexW4390956295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.